Generic-drug makers are likely to see a boost this year, and Roseanne Ott of the Alger Health Sciences Fund likes Teva and Mylan in particular.
http://www.thestreet.com/story/10457591/1/biotech-generics-will-lead-health-stocks-in-2009.html?puc=_tscrss